Anna Marie Soriano Samson
Family · Lake Elsinore, CANPI 1902150865
Payments from drug & device makers
Across 324 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$708
- AstraZeneca$680
- Novo Nordisk$541
- AbbVie$428
- Tandem Diabetes Care, Inc.$386
- Lilly USA, LLC$328
- plus $4K from 32 others
What the payments were for
- Food & beverage$7,172100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 35 | $708 |
| AstraZeneca | 22 | $680 |
| Novo Nordisk | 37 | $541 |
| AbbVie | 16 | $428 |
| Tandem Diabetes Care, Inc. | 16 | $386 |
| Lilly USA, LLC | 15 | $328 |
| Xeris Pharmaceuticals, Inc. | 15 | $315 |
| Cequr Corporation | 4 | $294 |
| Medtronic | 12 | $277 |
| Johnson & Johnson | 8 | $273 |
| Ascensia Diabetes Care US Inc. | 12 | $269 |
| Amarin Pharma, Inc. | 20 | $266 |
| Kowa Pharmaceuticals America, Inc. | 12 | $248 |
| Insulet Corporation | 16 | $238 |
| Bayer | 10 | $219 |
| Pfizer | 10 | $196 |
| Dexcom, Inc. | 8 | $184 |
| Esperion Therapeutics, Inc. | 4 | $163 |
| Eisai Inc. | 8 | $142 |
| Ascendis Pharma Endocrinology Inc | 4 | $128 |
| Sanofi-aventis U.S. LLC | 6 | $127 |
| Amgen(2 entities) | 7 | $126 |
| Boehringer Ingelheim | 4 | $81 |
| GSK | 3 | $81 |
| Mannkind Corporation | 3 | $61 |
| Sequel Med Tech, LLC | 2 | $54 |
| Recordati_rare_diseases_inc. | 2 | $54 |
| Embecta Corp. | 2 | $46 |
| Bigfoot Biomedical Inc | 1 | $35 |
| Amphastar Pharmaceuticals, Inc. | 2 | $35 |
| Amryt Pharma Holdings Ltd | 1 | $34 |
| Madrigal Pharmaceuticals | 1 | $32 |
| Corcept Therapeutics | 1 | $31 |
| RGH Enterprises LLC | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Tolmar, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$233
- CeQur Simplicity$153
- UBRELVY$125
- FREESTYLE LIBRE 3$125
- XARELTO$125
- BREZTRI$108
- NEXLIZET$103
- NEXLETOL$103
How this compares
$7,172 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 464 | $498,353 |
| JardianceEmpagliflozin | 383 | $302,635 |
| FarxigaDapagliflozin Propanediol | 262 | $204,637 |
| TrulicityDulaglutide | 141 | $155,489 |
| MounjaroTirzepatide | 65 | $73,349 |
| RybelsusSemaglutide | 61 | $68,727 |
| JanuviaSitagliptin Phosphate | 53 | $37,841 |
| DapagliflozinDapagliflozin Propanediol | 50 | $35,523 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $30,054 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $29,565 |
| Humalog Kwikpen U-100Insulin Lispro | 83 | $28,838 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $28,117 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $24,554 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $24,083 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 17 | $23,301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $541 | $576,434558 claims |
| Boehringer IngelheimJardiance | $81 | $302,635383 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $328 | $239,154256 claims |
| AstraZenecaFarxiga | $680 | $204,637262 claims |
| BayerKerendia | $219 | $22,50623 claims |
| Johnson & JohnsonInvokana | $273 | $19,54920 claims |
| Cequr CorporationCequr Simplicity | $294 | $12,20127 claims |
| Sanofi-aventis U.S. LLCLantus | $127 | $1,92914 claims |
| AbbVieSynthroid | $428 | $1,04515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Lake Elsinore
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.